Login to Your Account

'Affordable innovation'

Fosun Pharma's Henlius closing in on China's first biosimilar nod; HLX-01 under review

By Alex Ho and Cornelia Zou
Staff Writers

Wednesday, November 8, 2017

HONG KONG – With a series of advancements in the area of biosimilar development, China's Shanghai Fosun Pharmaceutical Group Co. Ltd. is getting closer to becoming the first domestic company to market a biosimilar product in China. Fosun Pharma said its subsidiary, Shanghai Henlius Biotech Inc., has received a notice from the CFDA that its first marketing application, for a biosimilar rituximab, is officially under review.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription